CD274 and neoplasm: In an adjuvant setting, the IMpower-010 trial demonstrated an improvement in DFS among patients in stages II to IIIA with a tumor proportion score (TPS) for PD-L1 greater than 1%, with this group showing a significant benefit particularly when PD-L1 exceeded 50%.246 Contrary to that, there have been studies indicating no significant association between PD-L1 and MPR.247 Furthermore, the PEARLS trial recently showed in the subgroup analysis that there was no significant benefit from the experimental treatment for the subpopulation with PD-L1 levels greater than 50%.228